glp-1 market news today Drug Market: the rapid growth of the diabetes and obesity drugs GLP-1 Receptor Agonist Market Size,

But sooner or later, almost everyone on one asks the same question

Triple agonist (GLP-1/GIP/Glucagon), under clinical investigation

When branded therapies of semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) commanded high prices and faced prolonged shortages from late 2022 through early 2025, compounding pharmacies emerged as alternative providers offering lower-cost formulations

Learn why the FDA says these products werent FDA-approved and how you could recover money.

Dr Reddys launches oral semaglutide biosimilar tablets, offering broader access to diabetes and weight-loss therapies in India.